the health
transformation
knowledge portal
Joaquim Cardoso MSc
March 4, 2024
This abstract was extracted from the original article, published by ACS Publications and written by Petrina Kamya, Ivan V. Ozerov, Frank W. Pun, Kyle Tretina, Tatyana Fokina, Shan Chen, Vladimir Naumov, Xi Long, Sha Lin, Mikhail Korzinkin, Daniil Polykovskiy, Alex Aliper, Feng Ren, and Alex Zhavoronkov, on February 25, 2024.
Abstract
PandaOmics is a cloud-based software platform that applies artificial intelligence and bioinformatics techniques to multimodal omics and biomedical text data for therapeutic target and biomarker discovery.
PandaOmics generates novel and repurposed therapeutic target and biomarker hypotheses with the desired properties and is available through licensing or collaboration.
Targets and biomarkers generated by the platform were previously validated in both in vitro and in vivo studies.
PandaOmics is a core component of Insilico Medicine’s Pharma.ai drug discovery suite, which also includes Chemistry42 for the de novo generation of novel small molecules, and inClinico─a data-driven multimodal platform that forecasts a clinical trial’s probability of successful transition from phase 2 to phase 3.
In this paper, we demonstrate how the PandaOmics platform can efficiently identify novel molecular targets and biomarkers for various diseases.
To read the original publication, click here.
